Pressmeddelanden

(Stockholm, Sverige, 22 november 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.

Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB’s products and services. The project will use ISAB’s XposeALI in vitro exposure module.

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB’s aerosol generating platform PreciseInhale and its unique cell exposure module.

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.

Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Life Science Day, November 23, 2023.

(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in the US relating to PreciseInhale® with approval for a new patent.

Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB’s in vitro dissolution testing module, known for its precise prediction and comparison of how test generic formulations and originator products perform in the lung. DissolvIt provides a unique advantage for developers of complex generic inhaled therapies. DissolvIt testing is being adopted by a growing number of generic and novel biopharma companies.

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.

(Stockholm, Sverige, 29 augusti 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 23 August 2023) Inhalation Sciences AB will repay a 1.8 MSEK loan which was reported in the Q1 Report 2023. The loan will be repaid by the end of August 2023. The contractual due date for repayment is December 2023. The total amount including interest and setup fee is approx. 2.6 MSEK.

Inhalation Sciences Sweden AB:s (publ) (”Inhalation Sciences” eller “Bolaget”) styrelseledamot Mårten Winge har idag meddelat sin avsikt att lämna Bolagets styrelse. Valberedningen föreslår att man inte ersätter Mårten med ny ledamot i styrelsen.

Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) som avslutades den 9 maj 2023 har slutregistrerats. Den andra och sista delregistreringen av företrädesemissionen har registrerats vid Bolagsverket den 6 juli 2023.

The rights issue in Inhalation Sciences Sweden AB (publ) ("ISAB" or the "Company") which ended on May 9, 2023 has been finally registered. The second and last partial registration of the rights issue has been registered with the Swedish Companies Registration Office on July 6, 2023.

Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, the second order from the region in a week. The order includes in vitro modules for inhaled drug development.

Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.8 KEuro (1.47 MSEK), from an international distributor for Asia. The new order is for PreciseInhale, ISAB’s unique aerosol generation system, with additional modules.

Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.

The rights issue in Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) has been partially registered with the Swedish Companies Registration Office and paid subscribed shares (BTA) will thus be replaced by shares. The last day of trading in BTAs is June 14, 2023, and new shares are expected to be delivered to the shareholders' securities deposit/VP account on June 20, 2023.

Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har delregistrerats vid Bolagsverket och betalda tecknade aktier (BTA) kommer därmed att ersättas av aktier. Sista dag för handel med BTA är den 14 juni 2023 och nya aktier beräknas att bokas in på respektive aktieägares depå/VP-konto den 20 juni 2023.

(Stockholm, Sverige, 31 maj 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2023 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Formulations for Improved Delivery of Antimicrobials’ (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).

Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client’s two existing PreciseInhale systems.

Inhalation Sciences Sweden AB (publ) (“ISAB” eller ”Bolaget”) offentliggör idag utfallet av den företrädesemission av aktier som Bolaget offentliggjorde den 6 april 2023 (”Företrädesemissionen”). Företrädesemissionen tecknades till cirka 23,0 procent, varav cirka 14,2 procent tecknades med stöd av teckningsrätter och cirka 8,8 procent tecknades utan stöd av teckningsrätter. Cirka 57,0 procent tecknades av emissionsgaranter. Genom Företrädesemissionen tillförs Bolaget cirka 13,7 MSEK före avdrag för emissionskostnader. Emissionslikviden från Företrädesemissionen avses primärt användas för expansion av existerande tjänster och relevant organisation.

Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) today announces the outcome of the rights issue of shares that the Company announced on April 6, 2023 (the “Rights Issue”). The Rights Issue has been subscribed for a total of approximately 23.0 percent, of which approximately 14.2 percent was subscribed for with the support of subscription rights and approximately 8.8 percent was subscribed for without the support of subscription rights. Approximately 57.0 percent was subscribed by underwriters. Through the Rights Issue, the Company receives approximately MSEK 13.7 before deduction for issuing costs. The proceeds from the Rights Issue will primarily be used for expansion of existing services and relevant organization.

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 12 maj 2023 årsstämma i Huddinge. Vid stämman fattades bland annat följande beslut.

Idag, den 9 maj är sista dag för deltagande i Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av aktier (”Företrädesemissionen”). Det finns fortfarande möjlighet att teckna sig utan stöd av teckningsrätter via emissionsinstitutet Hagberg & Aneborn Fondkommissions hemsida.

Today on May 9, 2023, is the last day for participation in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of shares (the “Rights Issue”). There is still the possibility to subscribe for shares without the support of subscription rights through the website of the issuing agent Hagberg & Aneborn Fondkommission.

(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project, ISAB today announces that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company’s facilities in Sweden.

(Stockholm, Sweden, 4 May 2023) Almost 200 specialists registered for ISAB’s latest experts’ webinar, now available to view online on ISAB’s LinkedIn page. The webinar was co-hosted by ISAB CSO Per Gerde and Matt Reed from Coelus Bio. It demonstrated how high-precision preclinical in vivo data can provide more accurate clinical estimates that reduce risk in the clinical development of inhaled medicines.

2023 has started in line with our expectations and we continue to see a steady inflow of inquiries from various biopharma customers and good progress in ongoing collaborations. We look forward to a spring and summer represented by a high-level of customer activity including several value-creating activities to continue our growth projectory.

Idag, den 24 april 2023, inleds teckningsperioden för Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av aktier (”Företrädesemissionen”). Företrädesemissionen beslutades av styrelsen den 6 april 2023 med stöd av bemyndigande från årsstämman den 6 maj 2022. Teckningsperioden löper till och med den 9 maj 2023.

Today on April 24, 2023, the subscription period begins in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of shares (the “Rights Issue”). The Rights Issue was resolved by the Board of Directors on April 6, 2023, with support of the authorization from the Annual General Meeting on May 6, 2022. The subscription period runs until and including May 9, 2023.

Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) offentliggör idag det informationsmemorandum som upprättats med anledning av Bolagets tidigare meddelade företrädesemission av aktier (”Företrädesemissionen”). Informationsmemorandumet kommer finnas tillgängligt på Bolagets hemsida www.inhalation.se, på Stockholm Corporate Finance AB:s hemsida www.stockholmcorp.se samt på Spotlight Stock Markets hemsida www.spotlightstockmarket.com.

Inhalation Sciences Sweden AB (publ) (“ISAB” or the “Company”) today publishes the information memorandum prepared in connection with the Company’s previously announced rights issue of shares (the “Rights Issue”). The information memorandum will be available on the Company’s website www.inhalation.se, on Stockholm Corporate Finance AB’s website www.stockholmcorp.se and on Spotlight Stock Market’s website www.spotlightstockmarket.com.

(Stockholm, Sweden, 19 April 2023) Following its highly successful webinar on DissolvIt dissolution studies on March 30[th] – 300 people registered – Inhalation Sciences AB (ISAB) will release two new webinars in 2023. Each will be partnered and co-presented by an industry expert. The next, on May 2[nd] 2023, features in vivo exposures for inhaled medicines with ISAB’s PreciseInhale aerosol system showcased by Per Gerde, ISAB’s CSO and Founder, and inhalation expert Matt Reed from Coelus Bio. Register for the seminar below.

(Stockholm, 18 April 2023) Inhalation Sciences Sweden AB (ISAB) has completed all the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project. ISAB expects formal clearance to begin the experimental part of the planned study shortly. The study (contract 75F40122C00197, communicated by ISAB on 15 September 2022) is to evaluate the discriminative power of ISAB’s DissolvIt in vitro dissolution technology.

(Stockholm, Sverige, 11 april 2023) Inhalation Sciences AB meddelar att en uppdaterad Årsredovisning 2022, inklusive revisionsberättelsen, är nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 11 April 2023) Inhalation Sciences AB announces that it is now releasing an updated version of its Annual Report 2022 that includes the Audit Report (Revisionsberättelsen).

(Stockholm, Sweden, 11 April 2023) Inhalation Sciences AB announces that its Annual Report for 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sverige, 11 april 2023) Inhalation Sciences AB meddelar att bolagets Årsredovisning 2022 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till årsstämma den 12 maj 2023 kl. 13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl. 12.30.

Styrelsen för Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har, med stöd av bemyndigande från årsstämman den 6 maj 2022, beslutat om en nyemission av aktier om cirka 17,1 MSEK med företrädesrätt för ISAB:s aktieägare (”Företrädesemissionen”). Bolaget har erhållit teckningsförbindelser och garantiåtaganden om cirka 13,7 MSEK, vilket motsvarar cirka 80 procent av Företrädesemissionen. Syftet med Företrädesemissionen är att intensifiera utvecklingen av Bolagets kontraktsforskningstjänster. Vidare meddelar Bolaget att offentliggörandet av delårsrapporten för första kvartalet kommer senareläggas.

The Board of Directors of Inhalation Sciences Sweden AB (publ) (”ISAB” or the ”Company”) has with the support of the authorization from the Annual General Meeting on May 6, 2022, resolved on a new issue of shares of approximately MSEK 17.1 with preferential rights for ISAB:s shareholders (the “Rights Issue”). The Company has received subscription- and guarantee commitments of approximately MSEK 13.7, which corresponds to approximately 80 percent of the Rights Issue. The purpose of the Rights Issue is to intensify the development of the Company’s contract research services. Furthermore, the Company announces that the publication of the interim report for the first quarter will be postponed.

Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) project. The client has chosen ISAB’s DissolvIt[®] for the project, due to its outstanding accuracy in testing generic formulations against originator products to define bioequivalence and, potentially, IVIVC (In Vitro In Vivo correlation), both critical metrics in generic drug development.

Inhalation Sciences deltar på Stockholm Corporate Finance 15:e Life Science Kapitalmarknadsdagar den 8 - 9 mars 2023 på IVA konferenscenter i Stockholm. VD Manoush Masarrat presenterar den 9 mars kl. 10:00 den senaste utvecklingen och framtiden för bolaget.

Inhalation Sciences will take part in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on 8 - 9 March 2023 at IVA Conference Center in Stockholm. CEO Manoush Masarrat will present the latest developments and the future of the company on March 9 at 10:00 am.

(Stockholm, Sweden, 7 March 2023) On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The client has now confirmed the entire IRS order, totaling 118,484 Euro (approx. 1.3 MSEK), of which 50,000 Euro has already been paid.

(Stockholm, Sverige, 28 februari 2023) Inhalation Sciences AB meddelar att bolagets bokslutskommuniké 2022 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/